Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of Escalating Doses of LEO 43204 Applied Once Daily for Two Consecutive Days on Approximately 250 cm2 on Trunk and Extremities in Subjects With Actinic Keratosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1/PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Part 1: Subjects with 5 to 20 clinically typical, visible and discrete AKs on the arm~* Part 2: Subjects with 5 to 20 clinically typical, visible and discrete AKs on the extremities or trunk~Exclusion Criteria:~* Location of the treatment area~  * within 5 cm of an incompletely healed wound~ * within 5 cm of a suspected basal cell carcinoma (BCC) or squamous cell carcinoma (SCC)~* Prior treatment with ingenol mebutate gel on the treatment area~* Lesions in the treatment areas that have:~  * atypical clinical appearance (e.g., hypertrophic, hyperkeratotic or cutaneous horns) and/or~ * recalcitrant disease (e.g., did not respond to cryotherapy on two previous occasions)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- LEO 43204 (Type: EXPERIMENTAL): Open-label, dose-escalation, 2-day treatment
- LEO 43204 Dose 0.1% (Type: EXPERIMENTAL): LEO 43204 dose 0.1% once daily for two consecutive days
- LEO 43204 Dose 0.075% (Type: EXPERIMENTAL): LEO 43204 dose 0.075% once daily for two days
- Placebo (Type: PLACEBO_COMPARATOR): Placebo once daily for two days

Based on this trial design, predict the completion outcome and termination type (if applicable).